Quality assessment of platelet concentrates prepared by platelet rich plasma-platelet concentrate, buffy coat poor-platelet concentrate (BC-PC) and apheresis-PC methods

Singh, Ravindra Pratap; Marwaha, Neelam; Malhotra, Pankaj; Dash, Sumitra

doi:10.4103/0973-6247.53882

Cited by 72 publications

(73 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the fact that the platelet number may be responsible for these observed variations, a large study reported a poor correlation between platelet counts and specific growth factor concentrations. 18,44 However, other studies demonstrated a clear effect between the growth factor content of platelets and the biological activity that was induced. 45 Further, it is well known that besides the growth factors, platelets contain a variety of other proteins or chemokines, which also might influence the reaction of cells or tissues.…”

Section: Discussionmentioning

confidence: 95%

Platelet-Rich Plasma Can Replace Fetal Bovine Serum in Human Meniscus Cell Cultures

Gonzales

Mulder

Boer

et al. 2013

Tissue Engineering Part C: Methods

View full text Add to dashboard Cite

Concerns over fetal bovine serum (FBS) limit the clinical application of cultured tissue-engineered constructs. Therefore, we investigated if platelet-rich plasma (PRP) can fully replace FBS for meniscus tissue engineering purposes. Human PRP and platelet-poor plasma (PPP) were isolated from three healthy adult donors. Human meniscal fibrochondrocytes (MFCs) were isolated from resected tissue after a partial meniscectomy on a young patient. Passage-4 MFCs were cultured in monolayer for 24 h, and 3 and 7 days. Six different culture media were used containing different amounts of either PRP or PPP and compared to a medium containing 10% FBS. dsDNA was quantified, and gene expression levels of collagen types I and II and aggrecan were measured at different time points with quantitative polymerase chain reaction in the cultured MFCs. After 7 days, the dsDNA quantity was significantly higher in MFCs cultured in 10% and 20% PRP compared to the other PRP and PPP conditions, but equal to 10% FBS. Collagen type I expression was lower in MFCs cultured with medium containing 5% PRP, 10% and 20% PPP compared to FBS. When medium with 10% PRP or 20% PRP was used, expressions were not significantly different from medium containing 10% FBS. Collagen type II expression was absent in all medium conditions. Aggrecan expression did not show differences between the different media used. However, after 7 days a higher aggrecan expression was measured in most culture conditions, except for 5% PRP, which was similar compared to FBS. Statistical significance was found between donors at various time points in DNA quantification and gene expression, but the same donors were not statistically different in all conditions. At 7 days cell cultured with 10% PRP and 20% PRP showed a higher density, with large areas of clusters, compared to other conditions. In an MFC culture medium, FBS can be replaced by 10% PRP or 20% PRP without altering proliferation and gene expression of human MFCs.

show abstract

Section: Discussionmentioning

confidence: 95%

Platelet-Rich Plasma Can Replace Fetal Bovine Serum in Human Meniscus Cell Cultures

Gonzales

Mulder

Boer

et al. 2013

Tissue Engineering Part C: Methods

View full text Add to dashboard Cite

show abstract

“…[456] New trends in the preparation of platelets showed a shift toward the use of the buffy coat method. It has been suggested that this method causes less platelet activation and damage during platelet preparation.…”

Section: Introductionmentioning

confidence: 99%

Experience of buffy coat pooling of platelets as a supportive care in thrombocytopenic dengue patients: A prospective study

Chatterjee

Coshic

Borgohain

et al. 2014

Asian J Transfus Sci

View full text Add to dashboard Cite

Random donor platelet (RDP) is not sufficient to improve the platelet count in most thrombocytopenic patients. Single donor platelet (SDP) or buffy coat pooled platelet (BCPP) are the two choices to provide a full therapeutic dose of platelets. However, there are constraints in the preparation of SDP due to stringent donor selection procedure, time required for procedure, and need of special expensive equipments and kits. BCPP is widely practiced, especially in the European countries, since 1995. In India, we decided to adopt the procedure of buffy coat pooling of platelets, especially for economically backward patients and for emergencies. This study was prospectively conducted from September 2009 to September 2010. A total of 129 units of BCPP [tested prior for viral markers by enzyme-linked immunosorbent assay (ELISA) and individual donor nucleic acid amplification test (ID-NAT)] were issued to 129 patients suffering from dengue and were included in this study. For comparison between efficacy of SDP and BCCP, patients were divided into two groups of 50 each. The post-transfusion platelet counts of the patients were noted after 2 hours of transfusion for each type of component. The platelet yield varied from 2.5 to 4.4 Χ 1011 in BCPP samples. The samples analyzed were sterile without any contamination. The different biochemical parameters were analyzed in detail. The observed post-transfusion platelet recovery and corrected count increment (CCI) at 1 hour and 24 hours after BCPP transfusion were similar to that after SDP transfusion. Hence, we concluded that BCPP can be a low cost alternative to SDP in the times of emergencies like dengue and non-affordability by the patient for SDP.

show abstract

“…Platelet quality can be evaluated in vitro using several parameters such as visual appearance, metabolic activity, volume, platelet count, and WBC count per unit. After transfusion, platelet quality can be evaluated using corrected count increment (CCI) and percentage platelet recovery (PPR) [27,54].…”

Section: Quality Evaluation Indicators Of Apheresis Plateletmentioning

confidence: 99%

“…Singh et al [54] found that apheresis-platelet concentrate units from the CS3,000+ instrument showed better swirling and platelet counts than platelet rich plasma-platelet concentrates; however, Mintz et al [37] confirmed that spherical platelets may revert to the discoid form, and that non-discoid platelets may retain suitable functionality post-transfusion.…”

Section: Visual Appearancementioning

confidence: 99%

Plateletpheresis: the Process, Devices, and Indicators of Product Quality

Jang¹,

Kim²,

Kim³

et al. 2014

Journal of Life Science

View full text Add to dashboard Cite

Platelet products are used to treat hemorrhagic or platelet dysfunction diseases. Plateletpheresis involves collecting the platelet components of blood using an apheresis blood-collection system. Various indicators are available for evaluating the qualities of the apheresis platelets. The productivity of platelet collection is evaluated through both the collection efficiency and collection rates. Platelet storage quality can be evaluated in vitro using several indicators, including visual appearance, metabolic activities, volume, platelet count, white blood cell count, microparticles, and various platelet activation markers. Platelet activation markers have been used as indicators of storage quality in various studies. Post-transfusion platelet quality can be evaluated based on the corrected count increment and the percentage of platelet recovery. Although various studies have investigated the aspects of plateletpheresis, no article has systemically presented assessments of the platelet products obtained from different plateletpheresis devices. The present study provides a review of plateletpheresis, including the specifics of the process, the types of devices employed, the platelet quality, the overall efficacy, and the evaluation indicator qualities. Furthermore, the differences in functionality among the different apheresis devices are discussed. Although adverse reactions to the citrate anti-coagulant have been reported, apheresis processing may provide a safer option for donors who are at a high risk for presyncopal or syncopal reactions related to whole blood collection.

show abstract

Quality assessment of platelet concentrates prepared by platelet rich plasma-platelet concentrate, buffy coat poor-platelet concentrate (BC-PC) and apheresis-PC methods

Cited by 72 publications

References 29 publications

Platelet-Rich Plasma Can Replace Fetal Bovine Serum in Human Meniscus Cell Cultures

Platelet-Rich Plasma Can Replace Fetal Bovine Serum in Human Meniscus Cell Cultures

Experience of buffy coat pooling of platelets as a supportive care in thrombocytopenic dengue patients: A prospective study

Plateletpheresis: the Process, Devices, and Indicators of Product Quality

Contact Info

Product

Resources

About